| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/04/2002 | EP0783884B1 Conagenin as preventive and remedy for diarrhea |
| 09/04/2002 | EP0771209B1 Novel peptides |
| 09/04/2002 | EP0755443B1 Tissue-specific enhancer active in prostate |
| 09/04/2002 | EP0711355B1 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors |
| 09/04/2002 | EP0644880B1 1,2,3-triazole and imidazole compounds and their antitumor use |
| 09/04/2002 | CN1367830A Cancer associated antigens and uses therefor |
| 09/04/2002 | CN1367829A Compositions and methods for therapy and diagnosis of lung cancer |
| 09/04/2002 | CN1367828A Oligonucleotides for inhibiting expression of human eg5 |
| 09/04/2002 | CN1367826A Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 09/04/2002 | CN1367793A Neuromedin B and somatostatin receptor agonists |
| 09/04/2002 | CN1367792A Somatostatin agonists |
| 09/04/2002 | CN1367791A Novel angiogenesis inhibitor |
| 09/04/2002 | CN1367787A Water soluble SDZ-RAD esters |
| 09/04/2002 | CN1367778A Novel carboxylic acid derivatives with 5,6 substitutedpyrimidine ring, their production and utilization thereof as endothelin receptor antagonists |
| 09/04/2002 | CN1367704A Agent for gene therapy and for prevention of metastases, as well as for gene therapy of tumors |
| 09/04/2002 | CN1367702A Renal cell carcinoma treatment |
| 09/04/2002 | CN1367701A Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 09/04/2002 | CN1367695A Phthalazine derivatives for treating inflammatory diseases |
| 09/04/2002 | CN1367694A Camptothecin analogs and methods of preparation thereof |
| 09/04/2002 | CN1367690A Combination therapy using pentafluorobenzenesulfonamide |
| 09/04/2002 | CN1367686A Novel compositions |
| 09/04/2002 | CN1367684A Method and composition for treating solid tumors |
| 09/04/2002 | CN1367256A 2-demethyl 2-methoxy-hygrolidin, its preparation method and medicine composition using said compound as active effective component |
| 09/04/2002 | CN1367246A Nasopharyngeal carcinoma malignant transformation gene Tx gene DNA sequence and its determination method |
| 09/04/2002 | CN1367189A Method for modifying polylacticacid by adopting unsaturated cyclic anhydride or unsaturated cyclic imide, modified product and application |
| 09/04/2002 | CN1367179A Novel liver regeneration related protein, its code sequence and application |
| 09/04/2002 | CN1367169A Substituted 6,6-Hetero-dicycloderivative |
| 09/04/2002 | CN1367004A Medicine for curing cancers |
| 09/04/2002 | CN1366994A Medicine and its preparation |
| 09/04/2002 | CN1366989A Medicine for curing tumor and its preparation method |
| 09/04/2002 | CN1366949A Nano compound formula sarcandra preparation medicine and preparation method |
| 09/04/2002 | CN1366892A Nano qinghouyan preparation medicine and preparation method thereof |
| 09/04/2002 | CN1366881A Method for curing some cancers by using estrogenic excitomotor and agonist |
| 09/04/2002 | CN1366879A Inhibiting free radical compound resulting in cancer cell transfer |
| 09/04/2002 | CN1090022C Cancer treatment by photodynamic therapy, in combination with immunoadjuvant |
| 09/04/2002 | CN1090021C Preparation method and use of sulfated oligosaccharides |
| 09/04/2002 | CN1090020C 4,4-(disubstituted) cyclohexan-1-ols and related compounds |
| 09/03/2002 | US6444829 (2s,4r)-4-mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid n'-isobutyl-n'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators |
| 09/03/2002 | US6444823 Pyridyl alkane acid amides as cytostatics and immunosuppressives |
| 09/03/2002 | US6444820 Process for the manufacture of camptothecin derivatives |
| 09/03/2002 | US6444812 Intermediate compounds in the preparation of farnnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N-or C linked imidazoles |
| 09/03/2002 | US6444802 Human aminopeptidase |
| 09/03/2002 | US6444795 Anticancer agents |
| 09/03/2002 | US6444790 Peptidoglycan recognition proteins |
| 09/03/2002 | US6444686 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 09/03/2002 | US6444677 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/03/2002 | US6444657 2-(phosphonomethyl)pentanedioic acid; 2-(2-sulfanylethyl) pentanedioic acid; epithelial tissue scarring, collagen vascular disease, fibroproliferation, connective tissue disorder, respiratory distress syndrome; tgf regulator |
| 09/03/2002 | US6444644 Peptide having specified amino acid sequence; used for inhibition of thromboplastin |
| 09/03/2002 | US6444642 Administering to mammal effective amount of neuregulin polypeptide with p185.sup.erbb2 protein binding activity to stimulate myogenesis of muscle cells |
| 09/03/2002 | US6444639 Human chorionic gonadotrophin (hcg) used to treat or prevent tumors, multiple sclerosis, inflammation or angiogenesis-dependent diseases |
| 09/03/2002 | US6444434 Compounds inhibiting the activation of fx to fxa by tf/fviia. the compounds are anticoagulants. the invention also relates to a method of identifying a drug candidate. |
| 09/03/2002 | US6444431 Angiostatin receptor |
| 09/03/2002 | US6444233 Triterpene compositions and methods for use thereof |
| 09/03/2002 | US6444207 Binding with epitope of antigen; anticancer agents |
| 09/03/2002 | CA2263203C 3,6-ketal and enol ether macrolide antibiotics |
| 09/03/2002 | CA2237189C 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 09/03/2002 | CA2232985C Methods for treating cancers and restenosis with p21 |
| 09/03/2002 | CA2140626C Hydroxamic acid derivatives as metalloproteinase inhibitors |
| 09/03/2002 | CA2096841C Drug delivery porphyrin compositions and methods |
| 09/03/2002 | CA2001815C Products and methods for controlling the suppression of the neoplastic phenotype |
| 08/29/2002 | WO2002066681A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 08/29/2002 | WO2002066648A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | WO2002066647A2 Type 2 ctokine receptor and nucleic acids encoding same |
| 08/29/2002 | WO2002066636A2 T cell receptor variants expressed in mesenchymal cells and uses thereof |
| 08/29/2002 | WO2002066635A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof |
| 08/29/2002 | WO2002066626A2 Regulation of human mut/nudix nucleoside triphosphate pyrophosphohydrolase |
| 08/29/2002 | WO2002066624A2 Novel human protease and polynucleotides encoding the same |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066512A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 08/29/2002 | WO2002066498A2 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 08/29/2002 | WO2002066494A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 08/29/2002 | WO2002066492A2 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof |
| 08/29/2002 | WO2002066481A1 Pyrimidine derivatives for inhibition of cell-proliferation |
| 08/29/2002 | WO2002066478A1 Antagonists of gonadotropin releasing hormone |
| 08/29/2002 | WO2002066475A2 Tricyclic androgen receptor modulator compounds |
| 08/29/2002 | WO2002066470A1 Substituted alkylamine derivatives and methods of use |
| 08/29/2002 | WO2002066463A1 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors |
| 08/29/2002 | WO2002066462A1 Pyrazole derivatives against tgf overexpression |
| 08/29/2002 | WO2002066461A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/29/2002 | WO2002066459A1 Indole derivatives and their use as gnrh antagonists |
| 08/29/2002 | WO2002066458A2 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry |
| 08/29/2002 | WO2002066451A2 1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof |
| 08/29/2002 | WO2002066450A2 Anthrone derivatives and their use as ink inhibitors |
| 08/29/2002 | WO2002066445A1 Quinazoline derivatives |
| 08/29/2002 | WO2002066437A1 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone |
| 08/29/2002 | WO2002066435A1 Metal complexes and therapeutic uses thereof |
| 08/29/2002 | WO2002066431A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same |
| 08/29/2002 | WO2002066430A1 Tryptase inhibitors |
| 08/29/2002 | WO2002066428A2 Non-steroidal estrogen receptor ligands |
| 08/29/2002 | WO2002066421A1 Rgd-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects |
| 08/29/2002 | WO2002066420A2 Tryptase inhibitors |
| 08/29/2002 | WO2002066415A2 Non-steroidal modulators of estrogen receptors |
| 08/29/2002 | WO2002066075A2 Biotin-derivatives and their conjugates with chelating agents |
| 08/29/2002 | WO2002066073A1 Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression |
| 08/29/2002 | WO2002066069A1 Remedies for inflammatory/tumor diseases |
| 08/29/2002 | WO2002066064A1 Use of galanin-like peptide |
| 08/29/2002 | WO2002066061A1 Active oxygen generator containing photosensitizer for ultrasonic therapy |
| 08/29/2002 | WO2002066058A1 Modified anti-egfr antibodies with reduced immunogenicity |
| 08/29/2002 | WO2002066052A1 Use of a conjugate of il-6 and an il-6 receptor in tumor therapy |
| 08/29/2002 | WO2002066044A2 Method for dendritic cells based immunotherapy of tumors using combination therapy |